Keros Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 92

Employees

  • Stock Symbol
  • KROS

Stock Symbol

  • Share Price
  • $11.39
  • (As of Thursday Closing)

Keros Therapeutics General Information

Description

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Contact Information

Website
www.kerostx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 99 Hayden Avenue
  • Suite 120 (Building E)
  • Lexington, MA 02421
  • United States
+1 (617)
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 99 Hayden Avenue
  • Suite 120 (Building E)
  • Lexington, MA 02421
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Keros Therapeutics Stock Performance

As of 19-Nov-2026, Keros Therapeutics’s stock price is $11.39. Its current market cap is $224M with 19.6M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$11.39 $12.00 $8.98 - $22.55 $224M 19.6M 196K -$2.80

Keros Therapeutics Financials Summary

As of 30-Sep-2026, Keros Therapeutics has a trailing 12-month revenue of $40.8M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (15,852) (55,754) 129,834 917,607
Revenue 40,761 244,061 3,550 151
EBITDA (60,879) 93,406 (185,824) (152,177)
Net Income (61,726) 87,014 (187,353) (152,992)
Total Assets 307,371 338,021 615,886 370,025
Total Debt 15,110 16,883 18,861 14,444
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Keros Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Keros Therapeutics‘s full profile, request access.

Request a free trial

Keros Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Keros Therapeutics‘s full profile, request access.

Request a free trial

Keros Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commerci
Biotechnology
Lexington, MA
92 As of 2026

Waltham, MA
 

Pasadena, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Keros Therapeutics Competitors (38)

One of Keros Therapeutics’s 38 competitors is Dyne Therapeutics, a Formerly VC-backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dyne Therapeutics Formerly VC-backed Waltham, MA
Arrowhead Pharmaceuticals Corporation Pasadena, CA
U.S. Stem Cell Formerly VC-backed Sunrise, FL
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
BioCardia Formerly VC-backed Sunnyvale, CA
You’re viewing 5 of 38 competitors. Get the full list »

Keros Therapeutics Patents

Keros Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026236607-A1 Methods of using activin receptor type ii variants Pending 08-May-2025
WO-2025184284-A1 Methods of using activin receptor type ii signaling inhibitors Pending 27-Feb-2024
WO-2025174995-A1 Methods of using activin a and myostatin signaling inhibitors Pending 13-Feb-2024
WO-2025147483-A1 Methods of using activin receptor type ii chimeras Inactive 02-Jan-2024
AU-2024396254-A1 Methods of using activin receptor type ii signaling inhibitors Pending 08-Dec-2023 C07K14/71
To view Keros Therapeutics’s complete patent history, request access »

Keros Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Keros Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Keros Therapeutics‘s full profile, request access.

Request a free trial

Keros Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

32.77 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Keros Therapeutics’s complete esg history, request access »

Keros Therapeutics FAQs

  • When was Keros Therapeutics founded?

    Keros Therapeutics was founded in 2015.

  • Where is Keros Therapeutics headquartered?

    Keros Therapeutics is headquartered in Lexington, MA.

  • What is the size of Keros Therapeutics?

    Keros Therapeutics has 92 total employees.

  • What industry is Keros Therapeutics in?

    Keros Therapeutics’s primary industry is Biotechnology.

  • Is Keros Therapeutics a private or public company?

    Keros Therapeutics is a Public company.

  • What is Keros Therapeutics’s stock symbol?

    The ticker symbol for Keros Therapeutics is KROS.

  • What is the current stock price of Keros Therapeutics?

    As of 19-Nov-2026 the stock price of Keros Therapeutics is $11.39.

  • What is the current market cap of Keros Therapeutics?

    The current market capitalization of Keros Therapeutics is $224M.

  • What is Keros Therapeutics’s current revenue?

    The trailing twelve month revenue for Keros Therapeutics is $40.8M.

  • Who are Keros Therapeutics’s competitors?

    Dyne Therapeutics, Arrowhead Pharmaceuticals, U.S. Stem Cell, Alnylam Pharmaceuticals, and BioCardia are some of the 38 competitors of Keros Therapeutics.

  • What is Keros Therapeutics’s annual earnings per share (EPS)?

    Keros Therapeutics’s EPS for 12 months was -$2.80.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process